Autologous T-Cells Combined With Autologous OC-DC Vaccine in Ovarian Cancer
Status:
Terminated
Trial end date:
2019-01-01
Target enrollment:
Participant gender:
Summary
This is a phase-I clinical trial to determine the feasibility and safety of
Cyclophosphamide/Fludarabine Lymphodepletion and an immunomodulatory combination of
Interferon-alpha Bevacizumab and Aspirin followed by adoptive transfer of vaccine-primed ex
vivo CD3/CD28-costimulated peripheral blood autologous T cells and vaccination with whole
tumor vaccine administered intradermally in combination with Bevacizumab in patients with
recurrent ovarian cancer fallopian tube or primary peritoneal cancer. (Funding Source - FDA
OOPD)
Phase:
Phase 1
Details
Lead Sponsor:
Abramson Cancer Center of the University of Pennsylvania